HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kenji Cunnion Selected Research

RLS-0071

5/2023RLS-0071 Moderated Elevated Myeloperoxidase Level and Activity in an Asymptomatic Subject in Clinical Trial RLS-0071-101.
1/2021Classical complement pathway inhibition reduces brain damage in a hypoxic ischemic encephalopathy animal model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kenji Cunnion Research Topics

Disease

1Atherosclerosis
05/2023
1Animal Disease Models
05/2023
1Inflammation (Inflammations)
05/2023
1Hypoxia (Hypoxemia)
01/2021
1Peritonitis
01/2021
1Reperfusion Injury
01/2021
1Ischemia
01/2021
1Hypothermia
01/2021
1Brain Injuries (Brain Injury)
01/2021
1Hemolysis
09/2020

Drug/Important Bio-Agent (IBA)

2Peroxidase (Myeloperoxidase)IBA
05/2023 - 01/2021
2RLS-0071IBA
05/2023 - 01/2021
1EnzymesIBA
05/2023
1Peptides (Polypeptides)IBA
05/2023
1Complement System Proteins (Complement)IBA
01/2021
1AntibodiesIBA
09/2020

Therapy/Procedure

1Intraperitoneal Injections
01/2021